After decades of efforts, we have recently made progress into targeting KRAS mutations in
several malignancies. Known as the 'holy grail'of targeted cancer therapies, KRAS is the …

KRAS is the most commonly mutated oncogene in advanced, non-squamous, non-small cell
lung cancer (NSCLC) in Western countries. Of the various KRAS mutants, KRAS G12C is the …

Covalent inhibitors of KRASG12C have shown antitumor activity against
advanced/metastatic KRASG12C-mutated cancers, though resistance emerges and …

Rapid emergence of tumor resistance via RAS pathway reactivation has been reported from
clinical studies of covalent KRASG12C inhibitors. Thus, inhibitors with broad potential for …

KRAS is the most frequently mutated oncogene in cancer. Activating mutations in codon 12,
especially G12D, have the highest prevalence across a range of carcinomas and …

Simple Summary Rat sarcoma virus (RAS) GTP-ase proteins represent a key element in
cellular proliferation, growth, and differentiation. Three different isoforms of RAS proteins …

Although KRAS-activating mutations represent the most common oncogenic driver in non-
small cell lung cancer (NSCLC), various attempts to inhibit KRAS failed in the past decade …

KRAS mutations drive oncogenic alterations in numerous cancers, particularly in human
pancreatic ductal adenocarcinoma (PDAC). About 93% of PDACs have KRAS mutations …

The improved survival outcomes of patients with non-small-cell lung cancer (NSCLC),
largely owing to the improved control of systemic disease provided by immune-checkpoint …

Lung cancer is the second most frequently diagnosed cancer worldwide and a leading
cause of cancer-related deaths. Non-small cell lung carcinoma (NSCLC) represents 85% of …